Transformation Time For Minoryx With Leriglitazone Filing
EMA Submission For Rare Brain Disease Drug
Executive Summary
The Spanish biotech, formed in 2011, is preparing for the potential European launch of leriglitazone for X-linked adrenoleukodystrophy after the EMA accepted its file.